Wendell King

Board Member

Wendell King is the CEO of King Consulting, a consulting company working primarily in the genomics and medical device field.

Earlier, he held various positions with Medtronic, Inc. Medtronic is a Fortune “200”, Minneapolis-based, medical device company. Mr. King served as Vice President and General Manager of the BioInterface Division, Medtronic’s second largest division, which manufactured and marketed temporary and permanent pacing leads, diagnostic catheters, physiologic sensors and angioplasty catheters. Prior to becoming Vice President and General Manager, he was Director of Research and Development at Medtronic where he was responsible for developing numerous commercially successful new products.

After leaving Medtronic, Mr. King co-founded and served as CEO and Chairman of Angeion Corporation, a developer of medical device products. Mr. King raised more than $50 million in private financing to fund the development of Angeion and successfully took the company public. Angeion today is a NASDAQ traded company, traded under the MGCD symbol.

After Angeion, Mr. King co-founded Gateway Alliance, LLC. Gateway was an early-stage business incubator. Gateway Alliance founded several successful companies including: Vascular Solutions, Rave Sports, and

Vascular Solutions, Inc., successfully completed an IPO and is a publicly traded medical device company and trades on the NASDAQ stock exchange.

Mr. King has numerous publications and has been granted more than 40 patents. He earned a B.S. in engineering physics from the University of Minnesota, Institute of Technology. Mr. King has completed the Executive Business Administration Program at Dartmouth, Amos Tuck School of Business, and course work toward a Ph.D. in polymer physics at the University of Akron, Polymer Institute.

In addition to Immusoft, Mr. King currently serves on the following Boards: Recombinetics and Cardiology Prevention.